The more recent Ma-Spore ALL 2010 trial did not use anthracyclines in LR while administering a cumulative vincristine dose of 28.5 mg/m2 leading to a 10-year EFS of 95% with 20% of this cohort being ETV6::RUNX1 ALL [57]. This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.